Aytu Biopharma (AYTU) Net Margin (2013 - 2025)

Aytu Biopharma (AYTU) has 13 years of Net Margin data on file, last reported at 0.41% in Q2 2025.

• On a quarterly basis, Net Margin rose 890.0% year-over-year to 0.41% in Q2 2025; TTM through Mar 2026 was 0.11%, a 114.0% increase from a year earlier, with the FY2025 full-year figure at 0.93%, up 603.0% from the prior year.
• Net Margin for Q2 2025 stood at 0.41%, up from 0.29% in the prior quarter.
• Over the last five years, Net Margin for AYTU reached as high as 25.36% in Q2 2022 and fell as low as 220.22% in Q1 2022.
• Historically, Net Margin has averaged 31.56% across 5 years, with a median of 4.48% in 2023.
• Across the five-year window, Net Margin slumped 9534 bps in 2021 and soared 18855 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 49.94% in 2021, then surged by 49 bps to 25.47% in 2022, then surged by 82 bps to 4.48% in 2023, then jumped by 117 bps to 0.76% in 2024, then sank by 46 bps to 0.41% in 2025.
• Per Business Quant data, the three most recent Net Margin figures were 0.41% in Q2 2025, 0.29% in Q1 2025, and 0.76% in Q4 2024.